Metabolism of roxithromycin in the isolated perfused rat liver

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 5, 1998, Pages 515-519

  Jarukamjorn, Kanokwan ^a,c   Thalhammer, Therese ^a   Gollackner, Bernd ^a   Pittenauer, Ernst ^b   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b FEDERAL RESEARCH AND TRAINING CENTRE FOR FORESTS   (Austria)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ROXITHROMYCIN;

ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER METABOLISM; LIVER PERFUSION; MASS SPECTROMETRY; NONHUMAN; RAT;

EID: 0031799395     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb06193.x     Document Type: Article

References (15)

1. Birkett, D. J., Robson, R. A., Grgurinovich, N., Tonkin, A. (1990) Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther. Drug Monit. 12: 65-71
2. Coutts, R. T., Su, P., Baker, G. B. (1994) Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isoenzymes in N-dealkylation reaction. J. Pharmacol. Toxicol. Methods 31: 177-186
3. Delaforge, M., Sartori, E., Mansuy, D. (1988) In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450: comparison with troleandomycin and erythromycin. Chem. Biol. Interact. 68: 179-188
4. Durant, J., Hazime, F., Pechere, J.C., Dellamonica, P. (1994) Prevention of Pneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients. Infection 23 (Suppl. 1): S33-S38
5. Guengerich, F. P. (1995) Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In: Pacifici, G. M., Fraccia, G. N. (eds) Advances in Drug Metabolism in Man. European Commission, Brussels, Belgium, pp 181-231
6. Hansen, K., Hovmark, A., Lebech, A. M. (1992) Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm. Venereol. 2: 348-350
7. Labenz, J., Borsch, G., (1994) Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 35: 19-22
8. Larrey, D., Funck-Brentano, C., Breil, P., Vitaux, J., Theodore, C., Babany, G., Pessayre, D. (1983) Effects of erythromycin on hepatic drug metabolizing enzymes in humans. Biochem. Pharmacol. 32: 1063-1068
9. Markham, A., Faulds, D. (1994) Roxithromycin, an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drug 48: 297-326
10. McLean, A., Sutton, J. A., Salmon, J., Chatelet, D. (1987). Roxithromycin: pharmacokinetic and metabolism study in humans. Br. J. Clin. Pract. 55: 52-53
11. Periti, P., Mazzei, T., Mini, E., Novelli, A. (1992) Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokin. 23: 106-131
12. Rodrigues, A. D., Roberts, E. M., Mulford, D. J., Yao, Y., Ouellet, D. (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug. Metab. Dispos. 25: 623-630
13. Rosing, H., Herben, V. M., van Gortel-van Zomeren, D. M., Hop, E., Kettenes-van den Bosch, J. J., ten Bockel Huinink, W. W., Beijnen, J. H. (1997) Isolation and structural confirmation of N-demethyl topotecan, a metabolite of topotecan. Cancer Chemother. Pharmacol. 39: 498-504
14. Thalhammer, T., Stapf, V., Gajdzik, L., Graf, J. (1994) Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport. Eur. J. Pharmacol. 270: 213-220
15. Yamazaki, H., Hiroki, S., Urano, T., Inoue, K., Shimada, T. (1996) Effect of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica 26: 1143-1153